Keyphrases
Tyrosine Kinase Inhibitor
100%
Chronic Myeloid Leukemia
100%
Medicare Part D
100%
Non-adherence
80%
Confidence Interval
40%
Odds Ratio
40%
Out-of-pocket Expenditure
40%
Tyrosine Kinase Inhibitor Therapy
40%
Logistic Regression
20%
Population-based Study
20%
Patient Characteristics
20%
Surveillance Epidemiology
20%
Multivariable Logistic Regression
20%
Patient Survival
20%
Registry Data
20%
Insurance
20%
Non-adherent
20%
Treatment Adherence
20%
Insurance Coverage
20%
Treatment Initiation
20%
Current Population
20%
Medicaid Patients
20%
Oral Therapy
20%
Low-income Subsidy
20%
Drug Supply
20%
Plan Characteristics
20%
Binary Variables
20%
Subsidies
20%
Treatment Nonadherence
20%
Cost Sharing
20%
Status Sharing
20%
Medicine and Dentistry
Medicare
100%
Chronic Myelogenous Leukemia
100%
Tyrosine-Kinase Inhibitor
100%
Health Care Cost
28%
Logistic Regression Analysis
28%
Odds Ratio
28%
Malignant Neoplasm
14%
Patient Compliance
14%
Surveillance, Epidemiology, and End Results
14%
Patient Characteristics
14%
Cost Sharing
14%
Nursing and Health Professions
Medicare
100%
Chronic Myeloid Leukemia
100%
Protein Tyrosine Kinase Inhibitor
100%
Odds Ratio
28%
Confidence Interval
28%
Logistic Regression Analysis
28%
Patient Compliance
14%
Malignant Neoplasm
14%
Pharmacology, Toxicology and Pharmaceutical Science
Protein Tyrosine Kinase Inhibitor
100%
Chronic Myeloid Leukemia
100%
Malignant Neoplasm
14%